Torrent Pharma-JB Chemicals merger: NCLT corrigendum 2026

What Torrent Pharma disclosed to exchanges

Torrent Pharmaceuticals Limited has confirmed it received a Corrigendum Order from the National Company Law Tribunal (NCLT), Ahmedabad Bench, linked to its ongoing amalgamation with J.B. Chemicals & Pharmaceuticals Limited. The corrigendum is dated March 24, 2026, and is described as a procedural clarification to the main tribunal order that sanctioned the merger. Torrent informed stock exchanges including BSE and NSE under SEBI listing regulations. The exchange intimation was signed by Company Secretary Chintan Trivedi. The companies are pursuing a court-approved scheme where J.B. Chemicals acts as the transferor company and Torrent Pharma as the transferee company. The update keeps the market informed on process milestones in a large consolidation in the Indian pharma sector.

Why the NCLT corrigendum matters

A corrigendum typically clarifies or corrects elements in an earlier order without changing the core decision. In this case, the tribunal has already sanctioned the amalgamation, and the corrigendum reinforces the legal record around that sanction. The development indicates procedural closure on points that needed clarification, rather than reopening the merits of the merger. For investors tracking the transaction, the corrigendum is important because it reduces ambiguity around the tribunal documentation. It also signals that the parties are moving through the final legal steps of corporate restructuring. The NCLT orders are central documents for schemes under Sections 230 to 232 of the Companies Act, 2013. With the corrigendum received and disclosed, the process moves further toward implementation conditions and shareholder processes described in the scheme.

Deal size and strategic context

Torrent Pharma first announced the transaction on June 29, 2025, positioning it as an acquisition of a majority stake in J.B. Chemicals in a deal valued at about ₹19,500 crore. The transaction was described as the second-largest deal in the Indian pharmaceutical sector, after Sun Pharma’s acquisition of Ranbaxy Laboratories in 2015. The strategic objective, as outlined across disclosures, is to scale Torrent’s domestic presence and broaden its portfolio. Torrent Pharma has said it expects to rank 5th in the Indian Pharmaceuticals Market after the amalgamation. It also expects a top-5 position in several therapy areas including cardiovascular, gastrointestinal, central nervous system, pain management, and cosmo-dermatology. Torrent, described as the flagship of the Torrent Group, reported annual revenues exceeding ₹11,500 crore, while the group had revenues around ₹45,000 crore.

How the acquisition is structured

The acquisition has been described as a multi-phase process combining stake purchases and a merger scheme. Torrent agreed to acquire a 46.39% stake from promoter Tau Investment Holdings Pte. Ltd., an affiliate of KKR, for about ₹11,917 crore. The deal terms also referenced a price of ₹1,600 per J.B. Chemicals share for the promoter block. Torrent also intended to acquire up to 2.80% from certain employees, with one disclosure putting this at about ₹719 crore. Following these steps, a mandatory open offer was launched to acquire up to 26% from public shareholders under SEBI takeover regulations, with the open offer component referenced at ₹6,842.8 crore. Separately, the transaction communication also referenced an equity valuation of ₹25,689 crore (fully diluted basis) in connection with the definitive agreements.

Share swap ratio and scheme mechanics

Boards of both companies approved the amalgamation scheme and swap ratio on November 11, 2025. Under the scheme, every shareholder holding 100 equity shares in J.B. Chemicals is to receive 51 equity shares of Torrent Pharmaceuticals. Disclosures also specify face values, with Torrent’s equity shares at ₹5 each and J.B. Chemicals’ equity shares at ₹1 each. The appointed date has been linked to Torrent’s completion of the promoter-share acquisition, and another disclosure specifies January 21, 2026 as the appointed date when Torrent completed acquisition of 74,481,519 promoter shares. The scheme also states that post-amalgamation, J.B. Chemicals will be dissolved without winding up. It further states that creditors of J.B. Chemicals will not face compromise, and all liabilities will be assumed by Torrent without reduction or extinguishment. Employees of J.B. Chemicals are to become employees of Torrent on terms no less favourable, with continuity of service and benefits.

Regulatory clearances: CCI and NCLT

Regulatory approvals have been a key part of the timeline. The Competition Commission of India (CCI) cleared the proposed acquisition on October 21, 2025, subject to voluntary modifications offered by the companies. On the NCLT side, the tribunal uploaded an order for the first motion application on March 23, 2026. The final order sanctioning the amalgamation is dated March 24, 2026. The corrigendum order is also dated March 24, 2026, and was uploaded on the NCLT website on March 25, 2026, as per the company update. In addition, disclosures mention that the scheme received no adverse observations from BSE and NSE. Valuation approaches cited include DCF, market price methods (SAST and ICDR), and NAV, with valuation reports by Ernst & Young and BDO Valuation Advisory LLP, and fairness opinions from Axis Capital and ICICI Securities.

Shareholder meetings and voting process

J.B. Chemicals published newspaper advertisements for an equity shareholders meeting scheduled for April 28, 2026 to consider the scheme. The meeting is to be held via video conferencing, with remote e-voting available from April 24 to April 27, 2026. Torrent Pharmaceuticals also issued a notice to shareholders for a meeting convened by the NCLT to consider and approve the scheme on April 28, 2026, also via video or other audio-visual means, with the same remote e-voting window. Scheme documents and meeting materials were made available on the company website and on stock exchange platforms for shareholders. One disclosure also notes that the resolution is deemed passed on April 28, 2026. These steps matter because shareholder consent is a statutory requirement for schemes under Sections 230 to 232.

Key milestones at a glance

Financial and capital structure details disclosed

Disclosures around the scheme include specific capital structure outcomes. Post-merger, the combined entity’s authorised share capital is stated to increase to ₹255.3 crore. This authorised capital comprises 460.6 million equity shares of ₹5 each and 2.5 million preference shares of ₹100 each. The scheme also describes accounting treatment where equity shares will be issued at face value and net asset differences will be adjusted in capital reserves or retained earnings. Torrent also disclosed it was certified as capable of repaying listed non-convertible debentures (ISIN INE685A07082) totalling ₹142.84 crore at face value, carrying an 8.33% annual coupon and maturing on December 12, 2025. Another disclosure references acquisition-related costs of ₹10 crore as exceptional items for a quarter.

Market impact and sector significance

The transaction is framed by Torrent as a move to strengthen its position in the domestic formulations market and build scale across chronic therapies. The deal structure combines a control acquisition, a mandatory open offer under SEBI regulations, and a court-approved amalgamation to consolidate operations. If executed as described, Torrent expects a stronger footprint across therapy areas where both companies have presence, and stated aims include synergies, cost reduction, operational efficiencies, and diversification. The combination also highlights how large Indian pharma companies are using M&A to expand portfolios and improve reach in the Indian Pharmaceuticals Market. At the same time, the process underlines the importance of multi-agency clearances, including CCI review and NCLT scheme sanction. With the corrigendum issued as a procedural clarification, the remaining visible steps in the disclosures are centred on shareholder meetings and completion of conditions precedent.

Conclusion

Torrent Pharma’s receipt of the NCLT Ahmedabad corrigendum order is a procedural update that strengthens the record for the tribunal’s sanction of its amalgamation with J.B. Chemicals. The merger follows a multi-phase acquisition plan valued at about ₹19,500 crore, including promoter stake purchase, employee purchases, and a mandatory open offer, alongside a 51:100 share swap scheme. Key regulatory steps include CCI approval on October 21, 2025 and NCLT orders in March 2026. The next major checkpoint disclosed by the companies is the shareholder meeting scheduled for April 28, 2026, with remote e-voting open from April 24 to April 27, 2026.